Feasibility, Biodistribution and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy (PTRT) of Diverse Adenocarcinomas using ¹⁷⁷Lu-FAP-2286: Firstin- Human Results.

Autor: Baum, Richard P., Schuchardt, Christiane, Singh, Aviral, Chantadisai, Maythinee, Robiller, Franz C., Jingjing Zhang, Mueller, Dirk, Eismant, Alexander, Almaguel, Frankis, Zboralski, Dirk, Osterkamp, Frank, Hoehne, Aileen, Reineke, Ulrich, Smerling, Christiane, Kulkarni, Harshad R.

Publikováno v: Journal of Nuclear Medicine; Dec2021, Vol. 62 Issue 12, Following p1-32, 45p

Feasibility, Biodistribution and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy (PTRT) of Diverse Adenocarcinomas using ¹⁷⁷Lu-FAP-2286: First-in-Human Results.

Autor: Baum, Richard P., Schuchardt, Christiane, Singh, Aviral, Maythinee Chantadisai, Robiller, Franz C., Jingjing Zhang, Mueller, Dirk, Eismant, Alexander, Almaguel, Frankis, Zboralski, Dirk, Osterkamp, Frank, Hoehne, Aileen, Reineke, Ulrich, Smerling, Christiane, Kulkarni, Harshad R.

Publikováno v: Journal of Nuclear Medicine; 8/1/2021, Vol. 62 Issue 8, p1-45, 45p

Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using ¹⁷⁷ Lu-FAP-2286: First-in-Humans Results.

Autor: Baum RP; Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, Bad Berka, Germany.; Curanosticum Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, Wiesbaden, Germany., Schuchardt C; Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, Bad Berka, Germany., Singh A; Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, Bad Berka, Germany., Chantadisai M; Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, Bad Berka, Germany.; Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Bangkok, Thailand., Robiller FC; Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, Bad Berka, Germany., Zhang J; Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, Bad Berka, Germany.; Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore., Mueller D; Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, Bad Berka, Germany., Eismant A; Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, Bad Berka, Germany., Almaguel F; Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, Bad Berka, Germany.; Loma Linda University, Loma Linda, California; and., Zboralski D; 3B Pharmaceuticals GmbH, Berlin, Germany., Osterkamp F; 3B Pharmaceuticals GmbH, Berlin, Germany., Hoehne A; 3B Pharmaceuticals GmbH, Berlin, Germany., Reineke U; 3B Pharmaceuticals GmbH, Berlin, Germany., Smerling C; 3B Pharmaceuticals GmbH, Berlin, Germany., Kulkarni HR; Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, Bad Berka, Germany; harshad.kulkarni@zentralklinik.de.

Publikováno v: Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2022 Mar; Vol. 63 (3), pp. 415-423. Date of Electronic Publication: 2021 Jun 24.